Do analysts rate ALVR or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ALVR or RDHL?

Redhill Biopharma has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Redhill Biopharma $286K 14.52 -$430K $1.05 thousand 0.00

Is ALVR or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Redhill Biopharma N/A N/A N/A

Do analysts rate RDHL or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 367.09%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is RDHL or CLRB more profitable?

Redhill Biopharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Cellectar Biosciences N/A -349.24% -153.18%

Do analysts recommend RDHL or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation & earnings, RDHL or MYNZ?

Redhill Biopharma has higher earnings, but lower revenue than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma $286K 14.52 -$430K $1.05 thousand 0.00 Mainz Biomed $659.94K 23.75 -$21.65M -$65.60 N/A

Is RDHL or MYNZ more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Mainz Biomed N/A N/A N/A

Do analysts prefer XCUR or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, XCUR or RDHL?

Redhill Biopharma has lower revenue, but higher earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 38.73 -$4.95M -$1.55 N/A Redhill Biopharma $286K 14.52 -$430K $1.05 thousand 0.00

Is XCUR or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Redhill Biopharma N/A N/A N/A

Does the media refer more to XCUR or RDHL?

In the previous week, Exicure had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Exicure and 4 mentions for Redhill Biopharma. Exicure's average media sentiment score of 0.57 beat Redhill Biopharma's score of 0.37 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RDHL or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,619.03%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is RDHL or MDCX more profitable?

Redhill Biopharma's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Medicus Pharma N/A -3,137.84% -311.33%

Does the media prefer RDHL or MDCX?

In the previous week, Medicus Pharma had 3 more articles in the media than Redhill Biopharma. MarketBeat recorded 7 mentions for Medicus Pharma and 4 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.37 beat Medicus Pharma's score of 0.30 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Redhill Biopharma (RDHL) Competitors

$0.80 -0.01 (-1.23%)

As of 03:04 PM Eastern

Compare

RDHL vs. ALVR, CLRB, MYNZ, XCUR, and MDCX

Should you buy Redhill Biopharma stock or one of its competitors? MarketBeat compares Redhill Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Redhill Biopharma include AlloVir (ALVR), Cellectar Biosciences (CLRB), Mainz Biomed (MYNZ), Exicure (XCUR), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does Redhill Biopharma compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Redhill Biopharma has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Redhill Biopharma	$286K	14.52	-$430K	$1.05 thousand	0.00

Redhill Biopharma's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Redhill Biopharma	N/A	N/A	N/A

In the previous week, Redhill Biopharma had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for AlloVir. Redhill Biopharma's average media sentiment score of 0.37 beat AlloVir's score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Redhill Biopharma	Neutral

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.1% of AlloVir shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Redhill Biopharma beats AlloVir on 10 of the 12 factors compared between the two stocks.

How does Redhill Biopharma compare to Cellectar Biosciences?

Redhill Biopharma (NASDAQ:RDHL) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 367.09%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

In the previous week, Redhill Biopharma had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for Redhill Biopharma and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.43 beat Redhill Biopharma's score of 0.37 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Cellectar Biosciences	Positive

Redhill Biopharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Cellectar Biosciences	N/A	-349.24%	-153.18%

Redhill Biopharma has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$286K	14.52	-$430K	$1.05 thousand	0.00
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Redhill Biopharma beats Cellectar Biosciences on 9 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to Mainz Biomed?

Redhill Biopharma (NASDAQ:RDHL) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Redhill Biopharma has a beta of 4.98, indicating that its share price is 398% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Redhill Biopharma had 4 more articles in the media than Mainz Biomed. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for Mainz Biomed. Redhill Biopharma's average media sentiment score of 0.37 beat Mainz Biomed's score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Mainz Biomed	Neutral

Redhill Biopharma has higher earnings, but lower revenue than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$286K	14.52	-$430K	$1.05 thousand	0.00
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A

7.2% of Redhill Biopharma shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Mainz Biomed	N/A	N/A	N/A

Summary

Redhill Biopharma beats Mainz Biomed on 7 of the 11 factors compared between the two stocks.

How does Redhill Biopharma compare to Exicure?

Exicure (NASDAQ:XCUR) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Redhill Biopharma has lower revenue, but higher earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	38.73	-$4.95M	-$1.55	N/A
Redhill Biopharma	$286K	14.52	-$430K	$1.05 thousand	0.00

Redhill Biopharma's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Redhill Biopharma	N/A	N/A	N/A

42.8% of Exicure shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has a beta of 3.53, meaning that its stock price is 253% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market.

In the previous week, Exicure had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Exicure and 4 mentions for Redhill Biopharma. Exicure's average media sentiment score of 0.57 beat Redhill Biopharma's score of 0.37 indicating that Exicure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Exicure and Redhill Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Redhill Biopharma compare to Medicus Pharma?

Redhill Biopharma (NASDAQ:RDHL) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

7.2% of Redhill Biopharma shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Medicus Pharma had 3 more articles in the media than Redhill Biopharma. MarketBeat recorded 7 mentions for Medicus Pharma and 4 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.37 beat Medicus Pharma's score of 0.30 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Redhill Biopharma has a beta of 4.98, meaning that its share price is 398% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Redhill Biopharma's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Medicus Pharma	N/A	-3,137.84%	-311.33%

Redhill Biopharma has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$286K	14.52	-$430K	$1.05 thousand	0.00
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,619.03%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Redhill Biopharma beats Medicus Pharma on 9 of the 14 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.15M	$2.98B	$6.48B	$12.36B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	0.00	18.53	23.95	24.60
Price / Sales	14.52	461.29	536.37	171.61
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.96	4.00	10.44	6.77
Net Income	-$430K	$75.79M	$3.56B	$337.32M
7 Day Performance	-21.57%	1.96%	0.83%	2.06%
1 Month Performance	-22.33%	-0.35%	1.78%	3.93%
1 Year Performance	-54.29%	23.23%	25.59%	32.29%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	1.0174 of 5 stars	$0.80 -1.2%	N/A	-53.7%	$4.15M	$286K	0.00	210
ALVR AlloVir	N/A	$4.17 -6.1%	N/A	+64.0%	$21.03M	N/A	N/A	110	High Trading Volume
CLRB Cellectar Biosciences	4.4095 of 5 stars	$2.36 -6.0%	$11.00 +366.1%	-82.0%	$20.06M	N/A	N/A	10	Positive News Gap Up
MYNZ Mainz Biomed	N/A	$2.20 -5.6%	N/A	-5.5%	$19.93M	$659.94K	N/A	30	High Trading Volume
XCUR Exicure	0.9807 of 5 stars	$2.85 -4.7%	N/A	-68.3%	$19.06M	$500K	N/A	50	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. ALVR, CLRB, MYNZ, XCUR, and MDCX

How does Redhill Biopharma compare to AlloVir?

Summary

How does Redhill Biopharma compare to Cellectar Biosciences?

Summary

How does Redhill Biopharma compare to Mainz Biomed?

Summary

How does Redhill Biopharma compare to Exicure?

Summary

How does Redhill Biopharma compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. ALVR, CLRB, MYNZ, XCUR, and MDCX

How does Redhill Biopharma compare to AlloVir?

Which has better valuation and earnings, ALVR or RDHL?

Is ALVR or RDHL more profitable?

Does the media prefer ALVR or RDHL?

Which has more volatility and risk, ALVR or RDHL?

Do analysts rate ALVR or RDHL?

Do institutionals & insiders have more ownership in ALVR or RDHL?

Summary

How does Redhill Biopharma compare to Cellectar Biosciences?

Do analysts rate RDHL or CLRB?

Which has more risk and volatility, RDHL or CLRB?

Does the media prefer RDHL or CLRB?

Is RDHL or CLRB more profitable?

Which has preferable valuation and earnings, RDHL or CLRB?

Do institutionals and insiders have more ownership in RDHL or CLRB?

Summary

How does Redhill Biopharma compare to Mainz Biomed?

Which has more risk and volatility, RDHL or MYNZ?

Do analysts recommend RDHL or MYNZ?

Does the media prefer RDHL or MYNZ?

Which has stronger valuation & earnings, RDHL or MYNZ?

Do institutionals & insiders believe in RDHL or MYNZ?

Is RDHL or MYNZ more profitable?

Summary

How does Redhill Biopharma compare to Exicure?

Which has higher earnings and valuation, XCUR or RDHL?

Is XCUR or RDHL more profitable?

Do institutionals and insiders believe in XCUR or RDHL?

Do analysts prefer XCUR or RDHL?

Which has more volatility and risk, XCUR or RDHL?

Does the media refer more to XCUR or RDHL?

Summary

How does Redhill Biopharma compare to Medicus Pharma?

Do insiders & institutionals hold more shares of RDHL or MDCX?

Does the media prefer RDHL or MDCX?

Which has more volatility & risk, RDHL or MDCX?

Is RDHL or MDCX more profitable?

Which has preferable valuation & earnings, RDHL or MDCX?

Do analysts rate RDHL or MDCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools